RxDoctor Payments Data

Lesleigh Thomas, PA

Physician Assistant · Concord, NCNPI 1962071415

Payments from drug & device makers

$3,704in general payments, 2019–2025

Across 166 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$451
  • Medtronic$427
  • Astellas Pharma US Inc$373
  • C. R. Bard, Inc. & Subsidiaries$363
  • Regeneron Healthcare Solutions, Inc.$207
  • Boston Scientific$197
  • plus $2K from 31 others

What the payments were for

  • Consulting fees$160%
  • Travel & lodging$2266%
  • Food & beverage$3,33190%
  • Education$1314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,704 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,033
Medicare patients
144
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron95$69,534
MyrbetriqMirabegron83$61,605
Solifenacin Succinate87$5,507
Tamsulosin Hcl311$4,861
Estradiol30$2,090
Finasteride178$1,707
Methenamine Hippurate33$1,610
Oxybutynin Chloride ErOxybutynin Chloride67$1,115
Oxybutynin Chloride46$810
Bethanechol Chloride15$721
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$585
Alfuzosin Hcl ErAlfuzosin Hcl25$567
Testosterone Cypionate11$415
Cephalexin22$407
Trospium Chloride14$332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$108$69,53495 claims
Astellas Pharma US IncMyrbetriq$373$61,60583 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →